Skip to main content

Table 1 Demographic data and clinical characteristics of all patients included in the study (n = 50)

From: Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients

Age (years) 69.4 ± 14.1 (25–90)
Men/women 31/19, 62 vs 38%
Body Mass Index (BMI, kg/m2) 26.1 ± 5.6 (13–44)
Dialysis (months) 65.1 ± 74.0 (5–470)
Diabetes (n, %) 23 (46)
Nephrosclerosis (n, %) 15 (30)
Autosomal Dominant Polycystic Disease (n, %) 4 (8)
Chronic glomerulonephritis (n, %) 8 (16)
Vasculitis/anti-GBM-nephropathy (n, %) 4 (8)
Ongoing medication with CNIs (n, %) 2 (4)
Ongoing medication with MMF (n, %) 1 (2)
Previousa treatment with CNI (n, %) 3 (6)
Previousa treatment with Rituximab or Cyclophosphamide (n, %) 5 (10)
Current systemic steroid treatment (n, %) 7 (14)
Previous renal transplant (n, %) 5 (10)
  1. Results are expressed as mean ± SD and range (min, max) or as proportions n (%)
  2. CNI, calcineurin inhibitors; MMF, mycophenolate mofetil; GBM, glomerular basement membrane
  3. aWithin the last ten years